AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease.

Alzheimer's disease (AD) is a progressive degenerative neurological disorder affecting nearly one in nine elderly people in the United States. Population studies have shown that an inheritance of the apolipoprotein E (APOE) variant APOE4 allele increases the risk of developing AD, whereas APOE2 homozygotes are protected from late-onset AD. It was hypothesized that expression of the "protective" APOE2 variant by genetic modification of the central nervous system (CNS) of APOE4 homozygotes could reverse or prevent progressive neurologic damage. To assess the CNS distribution and safety of APOE2 gene therapy for AD in a large-animal model, intraparenchymal, intracisternal, and intraventricular routes of delivery to the CNS of nonhuman primates of AAVrh.10hAPOE2-HA, an AAVrh.10 serotype coding for an HA-tagged human APOE2 cDNA sequence, were evaluated. To evaluate the route of delivery that achieves the widest extent of APOE2 expression in the CNS, the expression of APOE2 in the CNS was evaluated 2 months following vector administration for APOE2 DNA, mRNA, and protein. Finally, using conventional toxicology assays, the safety of the best route of delivery was assessed. The data demonstrated that while all three routes are capable of mediating ApoE2 expression in AD relevant regions, intracisternal delivery of AAVrh.10hAPOE2-HA safely mediated wide distribution of ApoE2 with the least invasive surgical intervention, thus providing the optimal strategy to deliver vector-mediated human APOE2 to the CNS.

[1]  J. Grieger,et al.  Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps , 2005, Journal of Virology.

[2]  David Eidelberg,et al.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.

[3]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[4]  Wood Ra,et al.  A comparison of ketamine, ketamine-acepromazine, and tiletamine-zolazepam on various hematologic parameters in rhesus monkeys (Macaca mulatta). , 1997 .

[5]  D. Holtzman,et al.  Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models , 2016, Neurobiology of Aging.

[6]  P. Aubourg,et al.  Enzyme, cell and gene-based therapies for metachromatic leukodystrophy , 2007, Journal of Inherited Metabolic Disease.

[7]  Robert R Hampton,et al.  Method for making selective lesions of the hippocampus in macaque monkeys using NMDA and a longitudinal surgical approach , 2004, Hippocampus.

[8]  David M Holtzman,et al.  Human Apoe Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance Nih Public Access , 2022 .

[9]  I. Martins,et al.  Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS , 2005, Gene Therapy.

[10]  D. Shera,et al.  Long-Term Follow-Up After Gene Therapy for Canavan Disease , 2012, Science Translational Medicine.

[11]  J. Wu,et al.  A novel mechanism of memory loss in Alzheimer’s disease mice via the degeneration of entorhinal–CA1 synapses , 2016, Molecular Psychiatry.

[12]  A. Ballabio,et al.  Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. , 2014 .

[13]  M. Curtis,et al.  Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[15]  J. Breslow,et al.  Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. , 1981, Biochemistry.

[16]  W. Pardridge,et al.  CSF, blood-brain barrier, and brain drug delivery , 2016, Expert opinion on drug delivery.

[17]  R. Crystal,et al.  365. Long-Term Toxicology Evaluation of AAVrh. 10hARSA Administration to the CNS of Nonhuman Primates to Treat Metachromatic Leukodystrophy , 2016 .

[18]  B. Hyman,et al.  Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain , 2013, Science Translational Medicine.

[19]  Christopher H Evans,et al.  Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs , 2014, Molecular pain.

[20]  M. Souweidane,et al.  Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. , 2015, Human gene therapy. Clinical development.

[21]  W. Low,et al.  Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I. , 2017, Human gene therapy.

[22]  J. Mendell,et al.  Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  R. Crystal,et al.  Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial , 2017, The Lancet Neurology.

[24]  P. Grandi,et al.  Viral vectors for therapy of neurologic diseases , 2017, Neuropharmacology.

[25]  M. Souweidane,et al.  Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. , 2008, Human gene therapy.

[26]  M. Chillón,et al.  AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy , 2014, Gene Therapy.

[27]  I. Martins,et al.  Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Foust,et al.  Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. , 2012, Human gene therapy.

[29]  P. Greengard,et al.  Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. , 1996, Annals of the New York Academy of Sciences.

[30]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[31]  D. Peterson,et al.  Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  M. Colle,et al.  Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats , 2014, Gene Therapy.

[33]  P. Aubourg.  Gene therapy for leukodystrophy: progress, challenges and opportunities , 2016 .

[34]  J. Kordower,et al.  Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases , 2011, Drug Delivery and Translational Research.

[35]  R. Mayeux,et al.  Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease , 2013, Nature Neuroscience.

[36]  Douglas R Martin,et al.  AAV Gene Therapy Strategies for Lysosomal Storage Disorders with Central Nervous System Involvement , 2015 .

[37]  J. Poirier,et al.  Odor identification as a biomarker of preclinical AD in older adults at risk , 2017, Neurology.

[38]  B. Wirth,et al.  Moving towards treatments for spinal muscular atrophy: hopes and limits , 2015, Expert opinion on emerging drugs.

[39]  Samantha Parker,et al.  Adeno-Associated Virus-Based Gene Therapy for CNS Diseases , 2016, Human gene therapy.

[40]  Stian Lydersen,et al.  APOE ε4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central Norway , 2008, BMC neurology.

[41]  B. Hermann,et al.  Naming Decline After Left Anterior Temporal Lobectomy Correlates with Pathological Status of Resected Hippocampus , 1998, Epilepsia.

[42]  S. Rumpel,et al.  Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain , 2013, PloS one.

[43]  Kathryn Hammond Rosenbluth,et al.  Analysis of a simulation algorithm for direct brain drug delivery , 2012, NeuroImage.

[44]  Y. Eto,et al.  Gene therapy for metachromatic leukodystrophy , 1996, Acta paediatrica Japonica : Overseas edition.

[45]  A. Heguy,et al.  High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  E. Portiansky,et al.  The ependymal route for insulin-like growth factor-1 gene therapy in the brain , 2009, Neuroscience.

[47]  R. Mahley.  Apolipoprotein E: Remarkable Protein Sheds Light on Cardiovascular and Neurological Diseases. , 2017, Clinical chemistry.

[48]  C. Jack,et al.  3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. , 2007, Brain : a journal of neurology.

[49]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Morris,et al.  Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[51]  T. Conlon,et al.  Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. , 2013, Human gene therapy.

[52]  C. O’Neill,et al.  Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease) , 2014, Journal of neuroscience research.

[53]  C. Buhmann,et al.  Characterization of four lipoprotein classes in human cerebrospinal fluid. , 2001, Journal of lipid research.

[54]  Radouil Tzekov,et al.  Vision function abnormalities in Alzheimer disease. , 2014, Survey of ophthalmology.

[55]  Alon Chen,et al.  Genetic approach for intracerebroventricular delivery , 2010, Proceedings of the National Academy of Sciences.

[56]  K. Hemsley,et al.  Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration , 2017, Journal of Molecular Medicine.

[57]  K. Weld,et al.  A comparison of ketamine, ketamine-acepromazine, and tiletamine-zolazepam on various hematologic parameters in rhesus monkeys (Macaca mulatta). , 1997, Contemporary topics in laboratory animal science.

[58]  S. Tabrizi,et al.  Therapies targeting DNA and RNA in Huntington's disease , 2017, The Lancet Neurology.

[59]  A. Smith,et al.  Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease , 1995, Neuroscience.

[60]  R. Crystal,et al.  Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates. , 2005, Human gene therapy.

[61]  M. Souweidane,et al.  Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. , 2010, Journal of neurosurgery. Pediatrics.

[62]  M. Lawrence,et al.  Clinical chemistry and hematology values in a Caribbean population of African green monkeys , 2010, Journal of medical primatology.

[63]  B. Rydenhag,et al.  Complications of Epilepsy Surgery after 654 Procedures in Sweden, September 1990–1995: A Multicenter Study Based on the Swedish National Epilepsy Surgery Register , 2001, Neurosurgery.

[64]  R. Samulski,et al.  Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates , 2012, Gene Therapy.

[65]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[66]  K. Bankiewicz,et al.  Controlled dissemination of AAV vectors in the primate brain. , 2009, Progress in brain research.

[67]  D. Shera,et al.  Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. , 2002, Human gene therapy.

[68]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[69]  M A Pericak-Vance,et al.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. , 1993, Neurology.

[70]  Sirkka Goebeler,et al.  Apolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age , 2009, Annals of neurology.

[71]  James M. Wilson,et al.  Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[72]  W. Fu,et al.  Drug candidates in clinical trials for Alzheimer’s disease , 2017, Journal of Biomedical Science.

[73]  J. A. Horel,et al.  THE NEUROANATOMY OF AMNESIA , 1978 .

[74]  B. Davidson,et al.  Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. , 2008, Human gene therapy.

[75]  Alzheimer’s Association.  2017 Alzheimer's disease facts and figures , 2017, Alzheimer's & Dementia.

[76]  F. Liu,et al.  Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice , 2009, The Journal of Neuroscience.

[77]  Inder M Verma,et al.  Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[78]  P. Bosco,et al.  APOE and Alzheimer disease: a major gene with semi-dominant inheritance , 2011, Molecular Psychiatry.

[79]  I. Bièche,et al.  Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. , 2010, Human molecular genetics.

[80]  R. Crystal,et al.  Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. , 2012, Human gene therapy.

[81]  J. A. Horel.  The neuroanatomy of amnesia. A critique of the hippocampal memory hypothesis. , 1978, Brain : a journal of neurology.

[82]  Sandro Alves,et al.  Gene Therapy Strategies for Alzheimer's Disease: An Overview. , 2016, Human gene therapy.

[83]  V. Labhasetwar,et al.  Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery , 2017, Journal of Neuroimmune Pharmacology.

[84]  R. Crystal,et al.  Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates. , 2014, Human gene therapy. Clinical development.

[85]  J. Weuve,et al.  Alzheimer disease in the United States (2010–2050) estimated using the 2010 census , 2013, Neurology.

[86]  A. Beutler.  AAV provides an alternative for gene therapy of the peripheral sensory nervous system. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[87]  C. Vite,et al.  Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals. , 2018, Human gene therapy.

[88]  K. Purpura,et al.  Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. , 2012, Human gene therapy methods.

[89]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[90]  T. Goldberg,et al.  APOE2 enhances neuroprotection against Alzheimer’s disease through multiple molecular mechanisms , 2014, Molecular Psychiatry.

[91]  D D Allen,et al.  The blood-brain barrier and brain drug delivery. , 2006, Journal of nanoscience and nanotechnology.

[92]  J. Mendell,et al.  Systemic Gene Delivery in Large Species for Targeting Spinal Cord, Brain, and Peripheral Tissues for Pediatric Disorders , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[93]  P Aebischer,et al.  Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6 , 2010, Gene Therapy.

[94]  B. Davidson,et al.  AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease , 2015, Science Translational Medicine.

[95]  N. Hackett,et al.  AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL , 2005, Gene Therapy.

[96]  M. Daulatzai.  Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer’s disease , 2015, Journal of Neural Transmission.

[97]  Xiaoying Tang,et al.  Shape and diffusion tensor imaging based integrative analysis of the hippocampus and the amygdala in Alzheimer's disease. , 2016, Magnetic resonance imaging.

[98]  D. Peterson,et al.  Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis , 2008, Experimental Neurology.